Pro Medicus (ASX:PME) has reported full-year revenue of $261.7 million for the year ended 30 June 2026, with underlying EBIT of $196.1 million and underlying NPAT of $144.7 million, according to the company's FY26 results filing. The company signed 10 new contracts and renewed six contracts during the period, with new contract wins totalling $407 million.

Key Points

  • Reported revenue of $261.7 million for FY26; constant currency revenue of $273.5 million, up 28.4% on an underlying basis
  • Underlying EBIT of $196.1 million at a margin of 74.9%; underlying NPAT of $144.7 million at a margin of 55.3%
  • Total dividend of 69.0 cents per share, fully franked, comprising a 32.0 cent interim and 37.0 cent final dividend
  • Forward contracts of A$1.34 billion over the next five years, up 41.3% in 12 months
  • Cash and financial assets of $252.3 million; NTA per share of $4.10

FY26 Financial Performance

Pro Medicus reported total revenue of $261.7 million for the year ended 30 June 2026, with North America contributing $236.8 million, Australia $19.0 million, and Europe $5.9 million. Underlying EBIT reached $196.1 million, representing a margin of 74.9%, up 0.9 percentage points. Underlying NPAT was $144.7 million at a margin of 55.3%, up 0.6 percentage points. Reported profit before tax was $377.5 million, which included a fair value gain on financial assets and interest of $174.2 million. Reported NPAT was $265.3 million. The company recorded a foreign exchange impact on revenue of negative $11.8 million, with the AUD/USD rate at 0.6779 compared to 0.6472 in the prior year.

Contract Wins, Renewals and Forward Contract Position

The company disclosed 10 new contracts signed during FY26, comprising one in Europe and nine in the United States, with a combined value of $407 million at contracted minimums. Six out of six contracts due for renewal were renewed on long-term, five-year extensions, valued at $141 million. Total contract value signed in FY26 was $548 million, described in the filing as the second highest year on record. Over a five-year period, the company has signed total contract value of $1.753 billion. Forward contracts representing recurring revenue over the next five years stood at A$1.34 billion, up 41.3% over 12 months.

Balance Sheet and Shareholder Returns

As of 30 June 2026, Pro Medicus held cash reserves of $216.1 million and cash and financial assets of $252.3 million. The company carried no borrowings. NTA per share was $4.10. The board declared a fully franked final dividend of 37.0 cents per share, bringing the total dividend for FY26 to 69.0 cents per share, compared with 55.0 cents per share in FY25. The effective tax rate was 29.7%. The filing also noted ongoing product developments including a digital pathology offering and an AI-optimised reporting module, as well as breast cancer detection software pending FDA clearance.